J
Joaquim Gama-Rodrigues
Researcher at University of São Paulo
Publications - 225
Citations - 9351
Joaquim Gama-Rodrigues is an academic researcher from University of São Paulo. The author has contributed to research in topics: Neoadjuvant therapy & Chemoradiotherapy. The author has an hindex of 43, co-authored 225 publications receiving 8380 citations. Previous affiliations of Joaquim Gama-Rodrigues include Universidade Estadual de Londrina & Instituto Adolfo Lutz.
Papers
More filters
Journal ArticleDOI
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Angelita Habr-Gama,Rodrigo Oliva Perez,Wladimir Nadalin,Jorge Sabbaga,Ulysses Ribeiro,Afonso Henrique da Silva e Sousa,Fábio Campos,Desidério Roberto Kiss,Joaquim Gama-Rodrigues +8 more
TL;DR: Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy and Surgical resection may not lead to improved outcome in this situation and may be associated with high rates of temporary or definitive stoma construction and unnecessary morbidity and mortality rates.
Journal ArticleDOI
Local Recurrence After Complete Clinical Response and Watch and Wait in Rectal Cancer After Neoadjuvant Chemoradiation: Impact of Salvage Therapy on Local Disease Control
Angelita Habr-Gama,Joaquim Gama-Rodrigues,Guilherme Pagin São Julião,Igor Proscurshim,Charles Sabbagh,Patricio B. Lynn,Rodrigo Oliva Perez +6 more
TL;DR: Local recurrence may develop in 31% of patients with initial cCR when early regrowths (≤ 12 months) and late recurrences are grouped together, and more than half of these recurrence develop within 12 months of follow-up.
Journal ArticleDOI
Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management?
Angelita Habr-Gama,Jorge Sabbaga,Joaquim Gama-Rodrigues,Guilherme Pagin São Julião,Igor Proscurshim,Patricia Bailão Aguilar,Wladimir Nadalin,Rodrigo Oliva Perez +7 more
TL;DR: Extended chemoradiation therapy with additional chemotherapy cycles and 54 Gy of radiation may result in over 50% of sustained (>12 months) complete clinical response rates that may ultimately avoid radical rectal resection.
Journal ArticleDOI
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Angelita Habr-Gama,Rodrigo Oliva Perez,Gregory Wynn,John H. Marks,Hermann Kessler,Joaquim Gama-Rodrigues +5 more
TL;DR: Strict definition of the clinical and endoscopic findings of patients experiencing complete clinical response after neoadjuvant chemoradiation therapy may provide a useful tool for the understanding of outcomes of patients managed with no immediate surgery allowing standardization of classifications and comparison between the experiences of different institutions.
Journal ArticleDOI
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy
Angelita Habr-Gama,Rodrigo Oliva Perez,Igor Proscurshim,Fábio Campos,Wladimir Nadalin,Desidério Roberto Kiss,Joaquim Gama-Rodrigues +6 more
TL;DR: Even though surgery remains the standard treatment for rectal cancer, nonoperative treatment after complete clinical response following neoadjuvant CRT may be safe and associated with good survival rates in a highly selected group of patients.